| Literature DB >> 35164167 |
Pengfei Guo1,2, Baoyue Zhang1,2, Jun Zhao1,2, Chao Wang1,2, Zhe Wang1,2, Ailin Liu1,2, Guanhua Du1,2.
Abstract
Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that currently has reached epidemic proportions among elderly populations around the world. In China, available traditional Chinese medicines (TCMs) that organically combine functional foods with medicinal values are named "Medicine Food Homology (MFH)". In this review, we focused on MFH varieties for their traditional functional features, substance bases, clinical uses, and mechanisms of action (MOAs) for AD prevention and treatment. We consider the antiAD active constituents from MFH species, their effects on in vitro/in vivo AD models, and their drug targets and signal pathways by summing up the literature via a systematic electronic search (SciFinder, PubMed, and Web of Science). In this paper, several MFH plant sources are discussed in detail from in vitro/in vivo models and methods, to MOAs. We found that most of the MFH varieties exert neuroprotective effects and ameliorate cognitive impairments by inhibiting neuropathological signs (Aβ-induced toxicity, amyloid precursor protein, and phosphorylated Tau immunoreactivity), including anti-inflammation, antioxidative stress, antiautophagy, and antiapoptosis, etc. Indeed, some MFH substances and their related phytochemicals have a broad spectrum of activities, so they are superior to simple single-target drugs in treating chronic diseases. This review can provide significant guidance for people's healthy lifestyles and drug development for AD prevention and treatment.Entities:
Keywords: Alzheimer’s disease; broad-spectrum activities; drug development; medicine food homology; traditional Chinese medicines
Mesh:
Substances:
Year: 2022 PMID: 35164167 PMCID: PMC8839204 DOI: 10.3390/molecules27030901
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
The clinical evidence of prevention and treatment of Alzheimer’s disease using MFH.
| No. | Registration No | Number of Subjects | Trial Period | Intervention Model | Intervention Group | Controlled Group | Findings/Mechanism | References |
|---|---|---|---|---|---|---|---|---|
| 1 | NCT00391833 | 77 patients | 12 weeks | An open-label study |
| Panax ginseng is clinically effective in the cognitive performance of AD patients. | [ | |
| 2 | 61 patients | 12-week | An open-label trial |
| Either donepezil, galantamine, memantine or rivastigmine | Korean red ginseng showed good efficacy for the treatment of Alzheimer’s disease | [ | |
| 3 | 91 patients | 24-week | A 24-week randomized open-label study | The effect of KRG on cognitive functions was sustained for 2-year follow-up, indicating feasible efficacies of long-term follow-up for Alzheimer’s disease. | [ | |||
| 4 | IRCT138711051556N1 | 91 patients | 22 weeks | A multicenter, randomized, double-blind controlled trial | Donepezil | This phase II study provides preliminary evidence of a possible therapeutic effect of saffron extract in the treatment of patients with mild-to-moderate Alzheimer’s disease. | [ | |
| 5 | 56 patients | 16 weeks | A randomized and placebo-controlled trial | Placebo | Saffron is both safe and effective in mild to moderate AD. | [ | ||
| 6 | 17 patients on crocus and 18 on a waiting list | 12 months | 1-year single-blind randomized, with parallel groups, clinical trial | Crocus is a good choice for management of aMCImd | [ | |||
| 7 | 24 participants |
| Donepezil | Cistanches Herba could improve cognitive and independent living ability of moderate AD patients, slow down volume changes of hippocampus, and reduce the levels of T-tau, TNF-α, and IL-1β. | [ |
MFH varieties and their functional features [21].
| Names | Parts to Be Consumed | Therapeutic Class | Features | |
|---|---|---|---|---|
| Chinese Name | English Name | |||
| Ren shen |
| Root | Qi-reinforcing medicinal | To reinforce the vital energy, to remedy collapse and restore the normal pulse, to benefit the spleen and lung, to promote the production of body fluid, and to calm the nerves. |
| Xi hong hua | Stigma | Blood-activating stasis removing medicinal | To activate blood circulation and eliminate blood stasis, to remove heat from blood and counteract toxicity, and to calm the nerves. | |
| Rou cong rong |
| Fleshy stem | Yang-reinforcing medicinal | To reinforce the kidney, replenish vital essence and blood, and induce taxation. |
| Dang gui | Root | Blood-tonifying medicinal | To enrich blood, activate blood circulation, regulate menstruation, relieve pain, and relax bowels. | |
| Huang qi | Root | Qi-reinforcing medicinal | To reinforce qi and invigorate the function of the spleen. | |
| Fu ling | Sclerotium | Diuretic dampness excreting medicinal | To cause diuresis, to invigorate the spleen function, and to calm the mind. | |
| Yi zhi ren |
| Fruit | Astringent medicinal | To warm spleen, check diarrhea, warm kidney, reduce urine, and secure essence. |
| Sheng jiang |
| Fresh rhizome | Pungent-warm exterior-releasing medicinal | To induce perspiration and dispel cold, to warm the stomach and arrest vomiting, and to resolve phlegm and relieve cough. |
| Yu zhu | Rhizome | Yin-tonifying Medicinal | To nourish yin, promote the production of body fluid, and relieve dryness syndromes. | |
| Gao liang jiang |
| Rhizome | Interior-warming medicinal | To warm the stomach and relieve vomiting, dispel cold, and relieve pain. |
| Xiang ru |
| Aerial parts | Pungent-warm exterior-releasing medicinal | To promote diaphoresis and release to the exterior, to resolve dampness and harmonize the spleen and stomach, to promote water metabolism and release edema |
| Hei hu jiao | Fruit | Interior-warming medicinal | To dispel cold from the stomach and to eliminate phlegm. | |
| Ling zhi | Dried sporocarp | Qi-reinforcing medicinal | To invigorate qi and calm the nerves and relieve cough and asthma. | |
| Sang shen | Ear of fruit | Yin-tonifying medicinal | To promote the production of body fluid. | |
| Jiang huang | Tuberoid | Blood-activating and stasis-dispelling medicinal | To eliminate blood stasis, promote the flow of qi, stimulate the release of menstruation, and relieve pain. | |
| Ge gen | Tuberoid | Pungent-warm exterior-releasing medicinal | To relieve fever, to promote the production of body fluid, to facilitate eruption, and to arrest diarrhea. | |
| Suan zao ren |
| Seed | Heart-nourishing tranquillizing medicinal | To replenish the liver, to cause tranquilizations, to arrest excessive perspiration, and to promote the production of body fluid. |
| Gan cao |
| Root, rhizome | Qi-reinforcing drugs | To reinforce the function of the spleen and replenish qi, to remove heat and counteract toxicity, to dispel phlegm and relieve cough, to alleviate spasmodic pain, and to moderate drug actions. |
| Lai fu zi | Seed | Digestants | To promote digestion and relieve abdominal distension and to relieve cough and resolve phlegm. | |
| Rou gui | Bark | Interior-warming medicinal | To supplement body fire, to reinforce yang, and to lead the fire back to the kidney, to dispel cold and relieve pain, and to activate blood circulation and stimulate menstrual discharge. | |
| Tian ma |
| Stem and tuber | Liver-pacifying and wind-extinguishing medicinal | To extinguish wind and check tetany, to calm liver and subdue yang, to dispel wind, and to free network vessels. |
| Gou qi zi | Fruit | Yin-tonifying medicinal | To benefit the liver and the kidney, to replenish vital essence, and to improve eyesight. | |
| Yu xing cao |
| Aerial parts | Heat-clearing and detoxicating medicinal | To remove toxic heat, to promote the drainage of pus, and to relieve dysuria. |
| Jue ming zi | Ripe seed | Fire-purging medicinal | To remove heat from the liver, to improve eyesight, and to relax bowels. | |
| Shan zhu yu |
| Fruit | Astringent medicinal | To replenish the liver and kidney, to restrain seminal discharge, and to relieve collapse. |
| Da zao |
| Ripe fruit | Qi-reinforcing medicinal | To tonify the spleen and replenish qi, to nourish blood, and to ease the mind. |
| Shi hu |
| Fresh or dried stems | Yin-tonifying medicinal | Treatment of thirst due to impairment to yin or deficiency of body fluid, loss of appetite with nausea, fever in deficiency conditions after a severe disease, and impaired vision. |
| Bi bo | Ear of fruit | Interior-warming medicinal | To warm the interior and expel internal cold | |
The mechanism of “Jun medicine” of MFH in TCM formulae against Alzheimer’s disease.
| No. | “Jun Medicine” of MFH | TCH Formulae | Dose Range | Controls | Experimental Models | Mechanism | References | |||
|---|---|---|---|---|---|---|---|---|---|---|
| In Vitro | In Vivo | Positive | Negative | In Vitro | In Vivo | |||||
| 1 |
| Shenma Yizhi Decoction (SMYZD) | 2.97, 11.88 g/kg | Wistar rats | ↑NG2, ↑Ang1, ↑PDGFR-β | [ | ||||
| Yizhi Qingxin Formula (YZQXF) | 0.3, 0.6 mg/kg | Donepezil hydrochloride | Distilled water | Wistar rats | ↑IL-10, ↓amyloid-β peptide, ↓TNFα, ↓IL2, ↓IL-6, ↑BDNF, ↑TrkB, ↑BDNF/TrkB pathway, ↑Erk and Akt signaling | [ | ||||
| 2.6, 5.2, 10.4 g·kg−1 | Distilled water | APP/PS1 mice | ↑LC3II/LC3I, ↑Beclin1, ↓mTOR, ↑4EBP1, ↓p62, ↑cathepsin D, ↑V-ATPase, ↓Aβ | [ | ||||||
| Jangwonhwan | 50, 75, 100, 150 µg/mL | 400 mg/kg | SH-SY5Y cells | APPswe/PS1De9 mice | ↓Abeta (1-42), ↓Abeta (1-40) | [ | ||||
| 2 | Danggui Buxue Tang (DGBXT) | 25, 50, 75, 100 µM | Cortical neurons | ↑Bcl2/Bax, ↓cleaved-caspase 3/9, ↓PARP | [ | |||||
| Danggui-Shaoyao-San (DGSYS) | 1.6, 3.2, 4.8 g/kg | SAMR1 and SAMP8 mice | ↑E2, ↑NO, ↑glycine | [ | ||||||
| 1.6, 3.2, 6.4 g/kg | Aricept | Saline | APP/PS1 mice | ↓PEG2, ↓TXB2, ↓LTB4, ↓cPLA2, ↓COX-1, ↓COX-2 | [ | |||||
| Fo Shou San (FSS) | 1.6, 3.2, 6.4 g/kg | Donepezil | Ultrapure water | APP/PS1 mice | ↓LPS, ↑AP, ↓MDA | [ | ||||
| 3 | Tiaoxin Recipe | 0.057 g/d | APPswe/PS1De9 mice | ↓amyloid plaque, ↓Aβ1-42 | [ | |||||
| Fuzheng Quxie Decoction (FZQXD) | 1.3, 2.6 g/kg | SAMP8 mice | ↓HIF1α | [ | ||||||
| 4 | Lingui Zhugan Decoction (LGZGD) | 4.8, 2.4 or 1.2 g/kg | Donepezil | Saline | Sprague–Dawley rats | ↓TNF-α, ↓IL-1β, ↓Aβ1-42, ↓p-Erk1/2, ↓p-p38, ↓p-NF-κB, ↓p-IκBα, ↓MAPK signaling, ↓NF-κB signaling | [ | |||
Extract from MFH on the role and mechanism of Alzheimer’s disease.
| No. | Extract of MFH | Dose Range | Controls | Experimental Models | Mechanism | References | |||
|---|---|---|---|---|---|---|---|---|---|
| In Vitro | In Vivo | Positive | Negative | In Vitro | In Vivo | ||||
| 1 |
| 1, 10, 100, 500, and 1000 μg/mL | 100 mg/kg | HT22 cells | 5XFAD mice | ↓Mitochondrial Dysfunction; ↓Aβ Deposits; ↓Neuroinflammation; ↓Neuronal Death | [ | ||
|
| 200 or 400 μg/mL | 400 and 800 mg/kg | Saline | HeLa cells | ICR mice; APP/PS1 mice | ↓Aβ42 | [ | ||
| 100 and 500 mg/kg | Saline | ICR mice | ↓cell death; ↓AβO1–42-induced microglial activation; ↑synaptophysin-positive areas; ↑optical density of ChAT immunoreactivity | [ | |||||
| Korean white ginseng, red ginseng extract, and black ginseng | 0.5, 2, 4, 6, 8 mg/mL | 2 mg/kg | 0.9% saline | Spectrophotometric method | ICR mice | ↓AChE; ↓BuChE | [ | ||
| 2 | 1, 10 μM | PC-12 cells | ↓caspase-3, ↓Bcl-XL mRNA | [ | |||||
| 3 | 1.2 g kg−1/day | APP/PS1 mice | ↓Aβ | [ | |||||
| 100, 300, 900 mg/kg | Fluoxetine | 0.5% carboxymethyl cellulose | Sprague–Dawley rats | ↓p38, ↓NF-κB, ↓TNF-α | [ | ||||
| 4 |
| 80, 120, 160, 200, 240 μg/mL | Cerebral cortices of BALB/c mouse | ↓glutamate-induced apoptosis | [ | ||||
| 20, 40, 60, 80, 100, 150, 200 μg/mL | 30, 60, 100, 150, 200 mg/mL | RSC96 Schwann cells | Sprague–Dawley rats | ↑uPA, ↑tPA, ↑MMP-9, ↑MAPKs, ↑Pas, ↑MMP9 signaling, ↑MEK1/2, ↑ERK1/2, ↑JNK1/2, ↑p38, ↑MMP-2, ↓TIMP-1, ↓TIMP-2 | [ | ||||
| 360 mg/kg | Donepezil | Saline | ICR mice | ↓IBA-1, ↓IL-1β, ↓Aβ1–42, ↓p-tau | [ | ||||
| 180, 360 mg/kg | Donepezil | Saline | ICR mice | ↑GSH-px, ↓MDA, ↓Aβ1–42 | [ | ||||
| 5 |
| 1, 2, 4 g/kg | Saline | Sprague–Dawley rats | ↓MDA, ↑SOD, ↑CAT, ↓NF-Κb, ↓IL-1β | [ | |||
| 50, 100, 200 mg/kg | Carboxymethyl cellulose | Wistar rats | ↓IL-1β, ↓GFAP | [ | |||||
| 0.13, 0.19, 0.25, 0.31 mg/mL | Rat brain | ↓AChE, ↓MDA | [ | ||||||
| 0.02, 0.1, 0.2 mg in 2 Μl of DMSO | Rat hippocampal | ↓Abeta oligomers | [ | ||||||
| 6 | 3% lyophilized 70% ethanol extracts | Hippocampal Slices of Sprague–Dawley rats | Insulin signaling, energy↑, glucose metabolism↑, tau protein↓ | [ | |||||
| 7 | 187.5 or 93.75 mg/kg | Aluminum chloride | Rats | ↑Ach, ↑TAC, ↑SOD, ↓AchE, ↓MDA, ↓NO | [ | ||||
| 50 mg/kg, 100 mg/kg | Diazepam | Wistar rats | ↓SOD, ↓GPX, ↓CAT, ↓GSH, ↓MDA | [ | |||||
| 8 | 0.1, 1, 10 μg/mL | 20 mg/kg, 100 mg/kg, and 500 mg/kg | Donepezil | Saline | Hippocampus of Sprague–Dawley rats | Sprague–Dawley rats | ↑GSK-3β, PI3k/Akt pathway, ↓tau hyperphosphorylation, ↑Bcl-2/Bax, ↓depolarization of the mitochondrial membrane, ↓cytochrome C release into the cytosol, ↓caspase-3 | [ | |
| 2, 10, 50 mg/kg | Donepezil | Wistar rats | ↓AChE, ↑Bcl-2-immunopositive neurons density, ↑GSH-Px | [ | |||||
| 50, 100, 500 mg/kg | SAMR1 and SAMP8 mice | ↓lipid oxidation, ↑antioxidant defense, ↓p38, ↓JNK, ↑ERK1/2, ↑Nrf2, ↓Aβ | [ | ||||||
| 200 μg/mL | PC12 cells | ↓Apaf1, ↓Bace2, ↓Plcb4 | [ | ||||||
| 9 | 340 mg/kg | Saline | C57BL/6J mice | ↓4HNE, ↑pS9-GSK3β, ↓Aß, ↑IDE, ↓pTau, ↑PSD95, ↑synaptophysin | [ | ||||
| 10 |
| 3, 30 μg/mL | Hippocampal of 5XFAD mice | ↑plasmin | [ | ||||
| 10, 30, 100 μg/mL | Hippocampal Slices of CD-1 mice | ↑BDNF, BDNF/TrkB signaling, ↑plasmin | [ | ||||||
| 20, 50, 100, 200, 400 µg/mL | PC12 cells | Caenorhabditis elegans | ↓Aβ-induced toxicity, ↓ROS | [ | |||||
| 11 | 0.75 mg/mL | 100 µg/mL | Water | 5XFAD mice | ↓Aβ species formation | [ | |||
| 500 μm | 100 mg/kg | BV-2 cells | 5XFAD mice | ↓ROS, ↓p21rac, ↑GSH, ↓GFAP, ↓Iba-1protein, ↓cleaved caspase 3, ↓tau phosphorylation, ↓Aβ | [ | ||||
| 50 mg/kg | Saline | Sprague–Dawley rat | ↓AChE, ↑GSK3β, ↓cholinesterase | [ | |||||
| 12 |
| 0.01, 0.05, 0.5, 1, 5, 10, 20 and 30 mg/mL | 50, 250, 500 mg/kg | Scopolamine | PC12 cells | Sprague–Dawley rats | ↓Neuronal cell death | [ | |
| 500, 1000 mg/kg | 0.5% cellulose | Rats | ↓Acetylcholinesterase | [ | |||||
| 13 | 10−4, 10−3, 10−2, 10−1, 1, 10, 102 μg/mL | Neurons of Sprague–Dawley rats | ↓caspase-3, ↓phospho-JNK-1, ↓phospho-c-Jun-I, ↓phospho-c-Jun-II | [ | |||||
| 14 |
| 400 mg/kg | Donepezil | Cortical neurons | Male ICR mice | ↓AChE | [ | ||
| 15 | 12.5, 25, 50, 100 mg/kg | ICR mice | ↓acetylcholinesterase | [ | |||||
| 1, 10 μg/mL | 50 mg/kg | Hippocampal | CD-1 mice | ↑GSK-3β, Akt signaling, ↓iNOS, ↓COX | [ | ||||
| 16 |
| 0.75, 1.5, 3 mg/mL | Astrocytes from postnatal SD rat | ↑NQO1, ↑GCLC, ↑GCLM, ↑GST | [ | ||||
| 0.75, 1.5, and 3.0 mg/mL | PC12 cells | PKA signaling, ↑CREB phosphorylation | [ | ||||||
| 0.375, 0.75, 1.5, and 3.0 mg/mL | RAW 264.7 macrophages | ↓IL-1β, ↓IL-6, ↓pNF-κB-Luc | [ | ||||||
| 17 |
| 40 mg/kg | Distilled water | Kunming mice | ↑BDNF, ↑GDNF, ↑CNTF | [ | |||
| 0.025, 0.25, 2.5 mg/L | Primary neuronal cultures | ↑PSD-95 mRNA, ↑SYP | [ | ||||||
| 3.5, 35, 350 ng/mL | Hippocampus tissues | ↓Aβ23-35 peptide cytotoxicity, | [ | ||||||
| 18 | 10 μL/g | 0.5% carboxymethyl cellulose | C57BL/6J mice | ↑NR2B, ↑ERK1/2, ↑CaMKIIα | [ | ||||
| 0.5, 1.0, 2.5 μM | 1.5, 3 mg/kg | DMSO + PBS | BV-2 cells | ICR mice | ↓APP, ↓BACE1, ↓COX-2, ↓iNOS, ↓translocation of NF-κB proteins (p50 and p65) to the nucleus, ↓IκB, ↓GFAP, ↓ IBA-1 | [ | |||
Active ingredients from MFH on the role and mechanism of Alzheimer’s disease.
| No. | Ingredients of MFH | Category | Source | Dose Range | Controls | Experimental Models | Mechanism | References | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| In Vitro | In Vivo | Positive | Negative | In Vitro | In Vivo | ||||||
| 1 | GinsenosideRg1 | Saponin |
| 20 mg/kg·d | Saline | SD rats | ↑SOX-2, ↓Aeg-1, ↑GSH-Px, ↑SOD, ↓IL-1β, ↓IL-6, ↓TNF-α, p53, ↓p21Cip1/Waf1, ↓p19Arf | [ | |||
| 2 | Ginsenoside Rh2 | Saponin | 1.5, 2.5, 3.5 μM | 10 mg/kg | Saline | Cortex neurons | tg2576 mice | ↓Abeta 1-40, ↓Abeta 1-42 | [ | ||
| 3 | Ginsenoside Rd | Saponin | 2.5 or 5 μmol/L | 10mg/kg | Saline | Cortical neurons | Sprague–Dawley rats | ↓tau hyperphosphorylation, ↑PP-2A | [ | ||
| 4 | Gintonin | Lysophosphatidic Acids-Protein Complexes | 0.1, 0.3, 1.0, 3.0, 10 μg/mL | B103 cells | transient Ca2+ mobilization, Gproteins/PLC/IP3 receptor/Ca2+ pathways | [ | |||||
| 5 | Ginsenoside compound K | Saponin | 50, 20, 10, 1 and 0 μM | Primary astrocytes | ↓Aβ, ↓mTOR signal pathway | [ | |||||
| 6 | Trans-Crocin 4/trans-Crocetin | 0.1, 1, 10, 100, 1000 μM | SH-SY5Y cells; PC12 cells | ↓BACE1, ↓γ-secretases (PSEN1 and PSEN2 complexes), ↓tau, ↓GSK3β, ↓ERK2, ↓pERK1, ↓pERK2 | [ | ||||||
| 7 | Tubuloside B | Phenylethanoid |
| 1, 10, or 100 mg/L | SH-SY5Ycells | ↓ROS, ↓caspase-3, ↓Ca2+ | [ | ||||
| 8 | Echinacoside | Phenylethanoid | 60 mg/kg | C57BL/6 mice | ↓HMGB1 | [ | |||||
| 9 | Vanillic acid | Aromatic acid | 25, 50, and 100 mg/kg | Swiss albinomice | ↓AChE, ↓corticosterone, ↓TNF-α | [ | |||||
| 10 | Decursinol | 2, 4, and 8 mg | ICR mice | ↓Aβ (1-40) induced memory impairment | [ | ||||||
| 0.01, 0.1, 1.0, 10 μM | PC12 cells | ↓ROS, ↑Bcl-2/Bax, ↑MMP, ↓cytochrome c, ↓Caspase-3 | [ | ||||||||
| 11 | Z-ligustilide | Aromatic ester | 40 mg/kg | Saline | SPF Wistar rats | ↓Aβ, ↓APP, ↓p-Tau, ↓NF-κB | [ | ||||
| 0.01, 1, 3, 10, 30 μM | SH-SY5Y cells; PC12 cells | p38/ PI3-K/Akt pathways | [ | ||||||||
| 12 | Astragaloside IV | Saponin | 25, 50, 100 μM | HT22 cells | ↑PPARγ/BDNF signaling pathway | [ | |||||
| 10.0 mg/kg | Saline | APP/PS1 mice | ↑PPARγ, ↓BACE1 | [ | |||||||
| 10, 25, 50 µM | SK-N-SH cells | ↓Bax, ↓caspase-3, ↑Bcl-2, ↓mPTP, ↓ROS | [ | ||||||||
| 13 | 5-Hydroxymethylfurfural | Furfural |
| 15, 150 μg/kg | Kunming mice | ↓β-secretase, ↓MDA, ↑GPx, ↑SOD | [ | ||||
| 14 | Tectochrysin | Flavonoid | 14 µg/kg | Donepezil | Kunming mice | ↑SOD, ↑GSH-px, ↓MDA | [ | ||||
| 15 | 6-gingerol | Olefinic alcohol |
| 40, 80, 120, 200, 300 μM | PC12 Cells | ↓ROS, ↓NO, ↓LDH, ↑SOD, ↓MDA, ↑p-Akt, ↑p-GSK-3β | [ | ||||
| 6 mg/kg | DMSO | C57BL/6N mice | ↑emotional memory deficit | [ | |||||||
| 10 mg/kg | Donepezil | Saline | ICR mice | ↑NGF, ↑PSD-95, ↑synaptophysin | [ | ||||||
| 16 | Narirutin | Flavonoid | 50, 100 mg/kg | APPswe/PS1dE9 mice | ↑CaMKII | [ | |||||
| 17 | Hesperidin | Flavonoid | 100 mg/kg | Saline | Wistar rats | ↓TBARS, ↑GSH, ↑SOD, ↑catalase, ↑GPx, ↓Bax, ↑Bcl-2 | [ | ||||
| 1, 3 and 9 μg/mL | 100 mg/kg | 1% CMC | RAW 264.7 cells | APP/PS1 mice | ↓Aβ plaques, ↓iNOS, ↓TNF-α, ↓IL-1β | [ | |||||
| 20, 40, 80 mg/kg | APP/PS1 mice | ↓TNF-α, ↓C-reactive protein ↓MCP-1, ↓NF-κB, ↑Akt, ↑GSK-3β (Ser 9), ↑Nrf2, ↑HO-1, ↓RAGE, ↓IκBα, ↓NF-κB/p65, ↑Akt/Nrf2 signaling, ↓RAGE/NF-κB signaling | [ | ||||||||
| 18 | Limonene (+) | Terpene | 50 μg/mL | Fly Strains | ↓Aβ42, ↓NO | [ | |||||
| 19 | Apigenin | Flavonoid | 40 mg/kg | 5% CMC-Na | APP/PS1 Mice | ↓Aβ, ↓BACE1, ERK1/2/CREB/BDNF pathway | [ | ||||
| 0.1, 1.0, 10.0 μM | SH-SY5Y cells | ↓AβPP, ↓ROS, ↑GSH, ↑SOD, ↑GSH-Px, ↓p38 MAPK signal pathway, ↓SAPK/JNK pathway | [ | ||||||||
| 1, 5 and 10 μM | BV-2 cells | ↓NO, ↓PGE2, ↓JNK, ↓p38 MAPK | [ | ||||||||
| Neuron/Glial Cells | ↓CD68, ↓OX42, ↓IL-6, ↓gp130, ↑BDNF | [ | |||||||||
| 20 | Galangin | Flavonoid |
| 6.25–400 μM | Rat adult brains | ↓AChE | [ | ||||
| 21 | β-Caryophyllene | Sesquiterpene | 16, 48, 144 mg/kg | APP/PS1 mice | ↓COX-2, ↓TNF-α, ↓IL-1β | [ | |||||
| 22 | Piperine | Alkaloid | 2.5, 5, 10, 25µM | Donepezil | SH-SY5Y cells | ↓AChE | [ | ||||
| 5 mg/kg | Donepezil | Saline | Wistar rats | ↓MDA, ↓NO | [ | ||||||
| 5, 10 and 20 mg/kg | Donepezil hydrochloride | Wistar rats | ↓lipid peroxidation, ↓acetylcholinesterase | [ | |||||||
| 23 | Curcumin | Polyphenol | 150 mg/kg | APP/PS1 mice | ↓NF-κB pathway, ↑PPAR-γ | [ | |||||
| 50 mg/kg | PBS | 5xFAD mouse | ↓Aβ, ↓GFAP-IR, ↓Iba-1-IR | [ | |||||||
| 24 | Aromatic-turmerone | Flavonoid | 5, 10 and 20 μM | HT-22 cells | ↓MMP-9, ↓iNOS, ↓COX-2, ↓TNF-α, ↓IL-1β, ↓IL-6, ↓MCP-1, ↓ROS, ↓IκB-α, ↓JNK, ↓p38 MAPK. | [ | |||||
| 5, 10 and 20 μM | 50, 100 mg/kg | PBS | BV2 cells | C57 mice | ↓TNF-α, ↓IL-1β, ↓Myd88, ↓MAPK, ↓NF-κB | [ | |||||
| 50 µg/mL | Cerebellar granule neuron | ↓cleaved caspase-3 | [ | ||||||||
| 25 | Puerarin | Isoflavone | 80 mg/kg | Saline | Sprague–Dawley rats | ↓tau hyperphosphorylation, ↓GSK-3β, ↓FGF-2 | [ | ||||
| 30 mg/kg | APP/PS1 transgenic mice | ↑HO-1, GSK-3β/Akt signaling pathways | [ | ||||||||
| 100 μM | PC12 cells | ↑Bcl-2, ↑p-Bad, ↓caspase-3, ↑Akt | [ | ||||||||
| 26 | Spinosin | C-glycoside flavonoid |
| 1.25, 2.5, 5 and 10 mg/kg | 0.5% CMC | ICR mice | ↑ERK–CREB–BDNF signaling | [ | |||
| 6.25, 12.5, 25 μM | Neuro-2a cells | ↓APP, ↓BACE1, ↑ADAM10, ↓ROS, ↑Nrf2, ↑HO-1, Nrf2/HO-1 signaling pathway | [ | ||||||||
| 10 and 100 µg/kg | Kunming mice | ↓MDA, ↓Aβ1–42, ↑BDNF, ↑Bcl-2, ↓IL-6 | [ | ||||||||
| 30 μM | Donepezil | 5XFAD hippocampus | ↑LTP, ↑plasmin | [ | |||||||
| 0.1, 1, and 10 μg/mL | 4, 20, 100 and 500 μg/mL | Donepezil | Hippocampus | ICR mice | ↑choline acetyltransferase | [ | |||||
| 27 | Liquiritin | Flavonoids |
| 25, 50, 100 mg/kg | Donepezil (3 mg/kg) | SD rats | ↑GSH-Px, ↑SOD, ↓8-OHdG, ↓MDA | [ | |||
| 28 | Glabridin | Flavonoid | 1, 2 and 4 mg kg–1 | Scopolamine (0.5 mg kg–1) | 0.3 % carboxymethyl cellulose suspension | Kunming mice | ↓cholinesterase | [ | |||
| 29 | Liquiritigenin | Flavonoid | 2.5, 5, 10, 20, 50, and 100 μM | 30 mg/kg | 0.1% sodium carboxymethyl cellulose | N2A cells; BV2 cells | APP/PS1 double transgenic mice | ↓NLRP3, ↓cleaved caspase-1, ↓caspase-3, ↓IL-1β, ↓TNF-α, ↑IL-4, ↑IL-13, ↓BAX, ↑Bcl-2, ↓Aβ, ↑NEP, ↑IDE | [ | ||
| 30 | Sulforaphene | Isothiocyanates | 0.5, 1, 2, 4, 8, 16, and 32 μM | 25, 50 mg/kg | Donepezil (5 mg/kg) | ddH2O | BV-2 cells | SD rats | ↓TNF-α; IL-6; ↑IL-10, ↑p-Akt (Ser473)/Akt, ↑p-GSK-3β (Ser9)/GSK-3β, ↓NO, ↓NF-κB | [ | |
| 31 | Gastrodin | Phenolic Glycosides |
| 60 mg/kg | Saline | Sprague–Dawley rats | ↓Aβ1-40/42, ↓APP, ↓β-site APP-cleaving, ↓Beclin-1, ↓LC3-II, ↓p62, ↓Bax, ↑Bcl-2, P38 MAPK signaling pathway | [ | |||
| 32 | P-coumaric acid | Phenylacrylic acid |
| 5, 25, 50 µM | PC12 cells | ↓BACE1, ↓iNOS, ↓p65, ↓ERK1/2, ↓JNK | [ | ||||
| 33 | Ursolic acid | Pentacyclic triterpenoids | 1,10, 20 µM | PC12 cells | ↓iNOS, ↓COX-2, ↓p65, ↓p-38, ↓JNK, ↓ERK | [ | |||||
Figure 1MFH antiAD network mechanism diagram. (Blue nodes represent MFH, and red nodes represent targets/pathways).
Figure 2The ingredients of MFH antiAD network mechanism diagram. (Blue nodes represent ingredient, and red nodes represent targets/pathways).
Figure 3Other active ingredients in MFH.
Figure 4The ingredients of Saponin in MFH.
Figure 5The ingredients of Flavonoid in MFH.